Persistence of Prolonged C-peptide Production in Type 1 Diabetes as Measured With an Ultrasensitive C-peptide Assay
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet; 1 of the 34 sources its claims cite were checked for support.
Abstract
OBJECTIVE: To examine persistence of C-peptide production by ultrasensitive assay years after onset of type 1 diabetes and factors associated with preserving β-cell function. RESEARCH DESIGN AND METHODS: Serum C-peptide levels, a marker of insulin production and surviving β-cells, were measured in human subjects (n = 182) by ultrasensitive assay, as was β-cell functioning. Twenty-two times more sensitive than standard assays, this assay's lower detection limit is 1.5 pmol/L. Disease duration, age at onset, age, sex, and autoantibody titers were analyzed by regression analysis to determine their relationship to C-peptide production. Another group of four patients was serially studied for up to 20 weeks to examine C-peptide levels and functioning. RESULTS: The ultrasensitive assay detected C-peptide in 10% of individuals 31-40 years after disease onset and with percentages higher at shorter duration. Levels as low as 2.8 ± 1.1 pmol/L responded to hyperglycemia with increased C-peptide production, indicating residual β-cell functioning. Several other analyses showed that β-cells, whose C-peptide production was formerly undetectable, were capable of functioning. Multivariate analysis found disease duration (β = -2.721; P = 0.005) and level of zinc transporter 8 autoantibodies (β = 0.127; P = 0.015) significantly associated with C-peptide production. Unexpectedly, onset at >40 years of age was associated with low C-peptide production, despite short disease duration. CONCLUSIONS: The ultrasensitive assay revealed that C-peptide production persists for decades after disease onset and remains functionally responsive. These findings suggest that patients with advanced disease, whose β-cell function was thought to have long ceased, may benefit from interventions to preserve β-cell function or to prevent complications.
Overview
CoChat Summary
## TL;DR
Using an ultrasensitive C-peptide assay in 182 people with type 1 diabetes, the paper found detectable C-peptide in some patients decades after diagnosis, including 10% at 31–40 years after onset. The detectable C-peptide was still functionally responsive to hyperglycemia, suggesting residual β-cell activity long after clinical onset.
## Key findings
- In 182 subjects, the ultrasensitive assay had a lower detection limit of 1.5 pmol/L, versus 15 pmol/L for the regular Mercodia assay and 33.1 pmol/L for the Cobas assay used in serial samples.
- Across disease-duration groups, detectable C-peptide declined over decades; rates above the detection limit were 78.9%, 59.5%, 39.5%, 39.1%, 10%, and 0% from the shortest to longest duration groups, and 10% of individuals had detectable C-peptide 31–40 years after onset.
- In serially studied patients, the ultrasensitive assay detected C-peptide in 34 of 54 samples (63%) when the standard assay was below detection in all 54/54 samples.
- Functional responsiveness persisted: samples with hyperglycemia had higher C-peptide than normoglycemia, including levels as low as 2.8 ± 1.1 pmol/L, and multivariate analysis found disease duration (β = −2.721; P = 0.005) and ZnT8 autoantibody level (β = 0.127; P = 0.015) were significantly associated with C-peptide production.
## Methods
- Observational study of 182 people with type 1 diabetes recruited over 10 years at Massachusetts General Hospital; most analyses used one fasting serum sample per participant, with 4 additional long-term patients followed serially for up to 20 weeks.
- Serum C-peptide was measured with a Mercodia ultrasensitive ELISA (detection limit 1.5 pmol/L) and compared with standard assays; autoantibodies GADA, IA-2A, and ZnT8A were measured, and glycemia was used to assess functional response.
- Statistical analysis used unpaired t tests with Welch correction, Pearson correlation, and univariate/multivariate regression; regression was limited to 125 patients with complete variables.
## Limitations
- The paper states that the age-at-onset analysis was incomplete/unfinished in the text provided, and the authors explicitly say the possible effect of onset after age 40 “needs to be confirmed in further studies, and in additional subject sets.”
- The study notes that regression analyses were limited to 125 of 182 patients because only those had all variables collected; this reduces the sample for multivariable inference.
- Evident from the design: it is a single-center observational study with a relatively small serial subgroup (4 patients), so causality cannot be inferred and the serial findings are based on few individuals.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
1 Valid · 1 Not valid · 18 Not checked · 29 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The strongest evidence to date, however, finds that while higher and sustained levels of C-peptide are most beneficial, even modest levels of β-cell function in some with long-term disease are associated with lower rates of hypoglycemia and lower incidence of retinopathy and nephropathy (9,11).”
§ Persistence of Prolonged C-peptide Production in Type 1 Diabetes as Measured With an Ultrasensitive C-peptide Assay > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [9] Panero, 2009, Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients, Diabetes Care source
- Supportedcites [11] Steffes, 2003, β-Cell function and the development of diabetes-related complications in the diabetes control and complications trial, Diabetes Care source
The Conclusions (p. 4) state that the observations 'emphasize the benefits of higher and sustained levels of C-peptide (and thereby insulin) secretion to reduce the incidences of the microvascular complications of type 1 diabetes,' and the abstract (p. 1) reports that 'any C-peptide secretion, but especially at higher and sustained levels of stimulated C-peptide, was associated with reduced incidences of retinopathy ... and nephropathy.' The same abstract page also supports the accompanying clause that 'even modest levels of β-cell activity at entry in the DCCT were associated with reduced incidences of retinopathy and nephropathy' and that continuing C-peptide secretion is important in avoiding hypoglycemia. Population and condition match: retrospective DCCT analysis in type 1 diabetes. (LLM, conf=0.90)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Considering the close correlation between duration and chronological age (r = 0.6757, P < 0.0001) (Supplementary Fig. 3C)”
§ Persistence of Prolonged C-peptide Production in Type 1 Diabetes as Measured With an Ultrasensitive C-peptide Assay > RESULTS > Multivariate analysis
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No substantial differences were found among the number of positive autoantibodies and C-peptide levels (Supplementary Fig. 3B).”
§ Persistence of Prolonged C-peptide Production in Type 1 Diabetes as Measured With an Ultrasensitive C-peptide Assay > RESULTS > Autoantibodies and sex
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Samples from hyperglycemic subjects had significantly higher C-peptide levels than did those from normoglycemic subjects in each of the C-peptide level ranges, except for the nonresponsive group, which had C-peptide levels below the level of detection of the ultrasensitive assay.”
§ Persistence of Prolonged C-peptide Production in Type 1 Diabetes as Measured With an Ultrasensitive C-peptide Assay > RESULTS > Functional capacity of β-cells in a large clinical sample
plainstates an associationn = 182- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 0–5 years group exhibited higher C-peptide levels than did the 6–10 years group (P = 0.0498).”
§ Persistence of Prolonged C-peptide Production in Type 1 Diabetes as Measured With an Ultrasensitive C-peptide Assay > RESULTS > Disease duration and C-peptide levels
plainstates an associationn = 182 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
18 more claims
Create a free account to see all 49 claims and to verify the 33 references still open.
- Probably not a substantial claim. 15
- It may state two separate claims as one. 15
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There have only been two small studies using sufficiently sensitive C-peptide assays from clinic based populations (n=74(1) and 182 (144 > 5years duration)(2)).”
From Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors (2015) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sensitive C-peptide assays have shown that 43-74% people with longstanding (> 5 years) type 1 diabetes (T1D) are microsecretors of endogenous insulin(1; 2) with C-peptide levels in a range not detected by previous assays (1-30 pmol/L).”
From Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors (2015) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The 2 previous smaller studies using sensitive C-peptide assays in T1D support the high prevalence in our study.”
From Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors (2015) · cites this paper as [2]
In the citing paper
“The study by Wang et al found a lower proportion (43% of 182 patients (median duration 15 years) (2) which probably reflected the use of a fasting sample and that the ELISA used was less sensitive than the chemiluminesence assay used in our two studies (1).”
From Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors (2015) · cites this paper as [2]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 23 · Cited by 192
Metadata
- Authors
- Wang, L., Lovejoy, N. F., & Faustman, D. L.
- Affiliations
- Harvard University (US)
- Corresponding author
- Wang, Limei
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-02-10
- Volume
- 35
- Issue
- 3
- Pages
- 465-470
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3322715
- OpenAlex
- W2100190220
- Cited by
- 192
- References
- 23
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 10 · 2023: 6 · 2022: 7 · 2021: 15 · 2020: 12 · 2019: 17 · 2018: 23 · 2017: 15 · 2016: 13 · 2015: 17 · 2014: 19 · 2013: 16 · 2012: 7
- FWCI
- 11.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 1 diabetes, C-peptide, residual beta-cell function, disease duration, zinc transporter 8 autoantibodies, age of onset, beta-cell preservation
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Biological Assay, C-Peptide, Child, Diabetes Mellitus, Type 1, Female, Humans, Male, Middle Aged, Reproducibility of Results, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Persistence of Prolonged C-peptide Production in Type 1 Diabetes as Measured With an Ultrasensitive C-peptide Assay. https://app.cochat.ai/papers/10.2337/dc11-1236
- The paper
- Wang, L., Lovejoy, N. F., & Faustman, D. L. (2012). Persistence of Prolonged C-peptide Production in Type 1 Diabetes as Measured With an Ultrasensitive C-peptide Assay. Diabetes Care. https://doi.org/10.2337/dc11-1236
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.